π Symbiotec Pharmalab IPO gets massive investor interest
Symbiotec Pharmalab's IPO saw an overwhelming subscription rate on its third day. Investors from various segments showed huge interest in the offering, which was managed through the primary market. The subscription crossed 5 times its issue size, while the Grey Market Premium (GMP) reached 36%. This strong performance signals significant market confidence in the pharmaceutical company's future prospects. The company is expected to proceed with the allotment process soon, based on this initial buzz. π